Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

• Status: Completed
• Trial end date: 2019-06-27
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanda Pharmaceuticals

Criteria

Inclusion Criteria:

• Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive);

• Body Mass Index (BMI) of ≥18 and ≤30 kg/m2;

• History or symptoms consistent with motion sickness

Exclusion Criteria:

• Chronic nausea due to condition other than motion sickness;

• A positive test for drugs of abuse at the screening or evaluation visits;

• Clinically significant deviation from normal clinical laboratory results